PTC Therapeutics Lifts 2026 Product Revenue Outlook To $960 Million-$990 Million After Sephience Sales Reach $181.9 Million

The rare-disease drugmaker posted a $51.7 million quarterly net loss after booking $111.0 million for a Fabry gene therapy it bought.

Share
PTC Therapeutics Lifts 2026 Product Revenue Outlook To $960 Million-$990 Million After Sephience Sales Reach $181.9 Million

PTC Therapeutics, which develops and sells medicines for rare disorders, raised its 2026 product revenue guidance to $960 million to $990 million from $850 million to $950 million, the company said Thursday in its third-quarter results. The same report showed a $51.7 million net loss, after a $111.0 million charge for buying a Fabry disease gene therapy.

Product sales more than double

Net product revenue across the portfolio was $275.9 million in the third quarter, against $131.0 million a year earlier, an increase of more than 100%, the company reported. Including royalties, revenue was $357.6 million, compared with $201.7 million a year earlier. Total 2026 revenue is now expected at $1.29 billion to $1.32 billion.

Sephience, the company's drug for the metabolic disorder phenylketonuria (PKU), brought in $181.9 million, up 20% from the second quarter. The US supplied $145 million and markets outside it $37 million, and more than 2,000 patients were on therapy worldwide as of September 30. Sephience revenue for the first nine months was $458 million, according to the company's presentation.

CEO Matthew B. Klein said the launch is "firmly on track to achieve our cash flow breakeven milestone this year."

Older drugs shrink, loss widens

Translarna sales slipped to $48.5 million from $50.7 million and included a purchase order from the Russian government. Emflaza fell to $25.1 million from $35.2 million. Royalties from Roche's Evrysdi added $81.7 million, against $70.8 million a year earlier.

The net loss compares with net income of $15.9 million a year earlier. Beyond the $111.0 million expense for ST-920, bought from Sangamo Therapeutics, the quarter carried a $19.3 million loss on extinguishing debt. Operating income was $25.1 million. Net interest expense was $45.9 million.

Cash and marketable securities stood at $2,127.9 million on September 30, against $1,945.4 million at the end of 2025. Total debt rose to $536.3 million from $286.6 million.

Fabry filing and Huntington's meeting

PTC paid $111.0 million upfront for ST-920, a one-time gene therapy for Fabry disease, with up to $100.0 million more tied to US approvals. It expects to finish its biologics license application in the fourth quarter, with possible accelerated approval and a launch in 2027.

An FDA meeting on votoplam, a Huntington's disease drug, is now set for the first quarter of 2027 because of FDA scheduling. The meeting will cover Phase 2 data and a possible accelerated approval path.

PTC's expense guidance is unchanged, at $775 million to $815 million on a standard-accounting basis for research and administrative costs combined.

Sources